RxDoctor Payments Data

John O'Mara, MD

Interventional Cardiology · Honolulu, HINPI 1548376601

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,240 of the $5,453 with a category attached, or 77.8%. Siemens Medical Solutions USA, Inc. accounts for 71.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $2,600 and has fallen 87.6% since, to $324 in 2023.

$5,453in general payments, 2019–2025

Across 26 payments — averaging $209.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$4K
  • Fujifilm Sonosite, Inc.$500
  • Edwards Lifesciences$293
  • AstraZeneca$175
  • Medtronic$173
  • Abiomed$173
  • plus $249 from 5 others

What the payments were for

  • Consulting fees$4,24078%
  • Food & beverage$1,03819%
  • Education$1753%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$6,487
Medicare patients
141
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab26$42,512
EliquisApixaban25$30,247
EntrestoSacubitril/Valsartan28$29,599
XareltoRivaroxaban21$26,726
PradaxaDabigatran Etexilate Mesylate93$23,439
JardianceEmpagliflozin32$17,211
Metoprolol Succinate175$2,289
Icosapent Ethyl12$1,507
Isosorbide Mononitrate ErIsosorbide Mononitrate37$696
ClopidogrelClopidogrel Bisulfate48$658
Losartan Potassium39$479
Amlodipine Besylate40$457
SotalolSotalol Hcl19$453
Amiodarone Hcl16$411
Spironolactone33$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$16$29,59928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →